NurExone Biologic chief executive Dr. Lior Shaltiel joins Proactive to talk about the company’s drug platform to treat damage in the Central Nerve System (CNS), which the company believes could have the potential to treat spinal cord injuries.
The firm recently announced its TSX Venture Exchange listing to gain access to investors and progress with its development of a novel, biological and minimally invasive treatment for spinal cord injury and traumatic brain injury.
